- Home
- Symposium Proceedings
Symposium Proceedings
View Video* of the Conference
Concurrent Sessions
Day 1 Keynote and Plenary Session
Day 2 Plenary Sessions
*where presenter permission was granted
View Pictures of the Conference
Photographs by Ed Cunicelli
Thursday, May 6, 2021
Agenda with Presentations
Log-in to Virtual Conference - Visit Virtual Exhibit Hall and Posters
Concurrent Sessions (Pre-Recorded) Begin and will be available Thursday May 6 and Friday May 7
There are a total of 8 tracks. Scroll left and right to view all tracks.
Track 1
Nursing
CNE-Accredited
Track 2 Pediatric Care
Track 3 Pre-Clinical / Manufacturing
Track 4 Next-Gen Clinical Research
Track 5 Regulatory and Commercial Development
Track 6 Solid Tumor CARs
Track 7 Financial Implications
Track 8 From Local to Global: Development of Engineered Cell & Gene Therapies
Track 1
Nursing
CNE-Accredited
9:00 am EDT
Introductions by:
Madeline Bell
Children’s Hospital of Philadelphia
Kevin B. Mahoney, DBA | Penn Medicine
Joint Adult and Pediatric Sessions - Nursing and Patient Care
State of the Union: Nursing in the Era of Cell and Gene Therapies
Regina Cunningham, PhD, RN, NEA-BC, FAAN | Penn Medicine
Ellen Tracy, RN, MSN, NEA-BC | Children’s Hospital of Philadelphia
Keynote Session: The Use of CRISPR Technology in the Treatment of Malignant and Non-Malignant Diseases
Making CAR T Cells "CRISPeR"
Edward A. Stadtmauer, MD | Penn Medicine
Adult Q&A Moderator: Patricia Mangan, MSN, CRNP | Penn Medicine
Nursing Considerations / Implications for Patients with SCD in the Era of Gene Tx
Claire M. White, MSN, RN | Children’s Hospital of Philadelphia
Elizabeth A. Worster, MSN, CRNP | Children’s Hospital of Philadelphia (Pediatric Q&A Moderator)
PRESENTATION
Pediatric Nursing Session
Moderator: Laura Smith, RN, MSN, CRNP | Children’s Hospital of Philadelphia
Immunotherapy in Pediatrics: AML/CART 33: Nursing considerations during COVID pandemic
Diane Baniewicz, RN, MSN, CRNP | Children’s Hospital of Philadelphia
PRESENTATION
Immunotherapy in Pediatrics: Nursing Considerations for U CART in Pediatrics
Colleen Callahan, RN, MSN, CRNP | Children’s Hospital of Philadelphia
PRESENTATION
Adult Nursing Session
Moderator: Patricia Mangan, MSN, CRNP | Penn Medicine
Preparing for an Autologous Stem Cell Transplant
Kelly Salam, RN, BSN | Penn Medicine
Keri McDevitt, RN, MSN, OCN | Penn Medicine
PRESENTATION
Preparing for an Allogenic Transplant
Rachel Golding, RN, BSN | Penn Medicine
Lila Quinn, BSN, RN, OCN | Penn Medicine
PRESENTATION
COVID Management of Liquid Oncology Patients
Abbey Walsh, MSN, RN, OCN | Penn Medicine
Angela M. Rubin, RN, BSN, OCN | Penn Medicine
PRESENTATION
Updates on Immunotherapies in Myeloma
Patricia Mangan, MSN, CRNP | Penn Medicine
PRESENTATION
Late Effects and Survivorship Care Following Donor Stem Cell Transplant: What to expect after the 1st year?
Linda M. Perry, MS, PA-C | Penn Medicine
PRESENTATION
Track 2 Pediatric Care 9:00 am EDT
Introductions by:
Stephan A. Grupp, MD, PhD | Children’s Hospital of Philadelphia
Future of Gene Therapy in Pediatrics Session
Moderator: Timothy S. Olson, MD, PhD | Children’s Hospital of Philadelphia
Clinical Overview/Impact
Timothy S. Olson, MD, PhD | Children’s Hospital of Philadelphia
PRESENTATION
Gene Therapy Techniques
Matthew Porteus, MD, PhD | Stanford University
PRESENTATION
Implication of Gene Therapy Treatment in Pediatrics Session
Moderator: Timothy S. Olson, MD, PhD | Children’s Hospital of Philadelphia
Hemoglobinopathies
Janet L. Kwiatkowski, MD, MSCE | Children’s Hospital of Philadelphia
Immune Deficiencies
Sung-Yun Pai, MD | National Institute of Health
(Consent to Post Not Granted)
Leukodystrophies
Amy T. Waldman, MD, MSCE | Children’s Hospital of Philadelphia
PRESENTATION
Track 3 Pre-Clinical / Manufacturing 9:00 am EDT
Introductions by:
Bruce L. Levine, PhD | Penn Medicine
Target Discovery and Immunogenicity Session
Moderator: Robert H. Vonderheide, MD, DPhil | Abramson Cancer Center
Antibody Discovery for New CAR Constructs
Donald L. Siegel, MD, PhD | University of Pennsylvania
PRESENTATION
Immune Responsiveness or Immune Ignorance?
Lisa Butterfield, PhD | Parker Institute for Cancer Immunotherapy
PRESENTATION
Immune Health
Robert H. Vonderheide, MD, DPhil | Abramson Cancer Center
PRESENTATION
Viral Vector Free Delivery Session
Moderator: Bruce L. Levine, PhD | Penn Medicine
Overview/Survey of Tech
Bruce L. Levine, PhD | Penn Medicine
PRESENTATION
Electro-Mechanical Transfection
Cullen R. Buie, PhD | Massachusetts Institute of Technology
(Consent to Post Not Granted)
Transient Cell Volume Exchange
Todd Sulchek, PhD | Georgia Institute of Technology
PRESENTATION
Enabling the Next Wave of Non-Viral Cell Therapies
Michael Maguire, PhD, CEO | Avectas
PRESENTATION
Gene Delivery and Editing for Better CARs Session
Moderator: Fyodor D. Urnov, PhD | University of California at Berkley
CRISPR and Beyond
Alexander Marson, MD, PhD | Gladstone-UCSF Institute of Genomic Immunology
PiggyBac and High-Fidelity Gene Editing for Fully Allogeneic CAR-T
Eric Ostertag, MD, PhD | Poseida
(Consent to Post Not Granted)
Sleeping Beauty in Trials
Laurence J.N. Cooper, MD, PhD | Ziopharm Oncology
Track 4 Next-Gen Clinical Research 9:00 am EDT
Introductions by:
David L. Porter, MD | Penn Medicine
Newest Model CARs Session
Moderator: Joseph A. Fraietta, PhD | University of Pennsylvania
Engineering Remote-Controllable CAR T Cells for Cancer Immunotherapy
Peter Yingxiao Wang, PhD | University of California San Diego
PRESENTATION
T Cell Antigen Couplers
Jonathan Bramson, PhD | McMaster University, Canada
(Consent to Post Not Granted)
in vivo CAR's
Christian Buchholz, PhD | Paul-Ehrlich-Institut, Germany
(Consent to Post Not Granted)
CAR's on the Unpaved Road Session
Moderator: James L. Riley, PhD | University of Pennsylvania
CAR's in Fibrosis
Jonathan A. Epstein, MD | University of Pennsylvania
PRESENTATION
CAARs for Antibody-mediated Autoimmune Disease
Michael C. Milone, MD, PhD | University of Pennsylvania
(Consent to Post Not Granted)
CAR's in HIV
James L. Riley, PhD | University of Pennsylvania
PRESENTATION
Allogeneic and Donor Derived CAR T Cells, NKs, iPSC's Session
Moderator: Melody Smith, MD, MS | Memorial Sloan Kettering Cancer Center
Allo CARs Intro
Melody Smith, MD, MS | Memorial Sloan Kettering Cancer Center
(Consent to Post Not Granted)
Making Allogeneic CAR T Therapy a Reality for Patients: A pathway to controlling rejection
David Chang MD, PhD | Allogene Therapeutics
(Consent to Post Not Granted)
FT536 – An iPSC-Derived, Off-the-Shelf Multiplexed Engineered CAR MICA/B NK Cell Product Targeting Solid Tumors
Bob Valamehr, PhD, MBA | Fate Therapeutics
(Consent to Post Not Granted)
Donor-Derived Gene-Edited Allogeneic CAR-T
Samarth Kulkarni, PhD | CRISPR Therapeutics
(Consent to Post Not Granted)
CAR-T Vaccine Booster Session
Moderator: Michael C. Milone, MD, PhD | University of Pennsylvania
RNA Vaccine Boosting CAR T Cells
Katharina Reinhard, PhD | Immunoreceptor Therapy
(Consent to Post Not Granted)
CD19 CAR T “Booster” T-APCs
Colleen Elizabeth Annesley, MD | Seattle Children’s Hospital
PRESENTATION
CMV Vaccine
Stephen J. Forman, MD | City of Hope
Track 5 Regulatory and Commercial Development 9:00 am EDT
Introductions by:
Bruce L. Levine, PhD | Penn Medicine
Managing Toxicities Session
Moderator: Noelle V. Frey, MD, MSCE | Penn Medicine
Consistency in Grading and Reporting
Stephan A. Grupp, MD, PhD | Children’s Hospital of Philadelphia
PRESENTATION
Pathophysiology of Neurotoxicity
Saad J. Kenderian, MB, ChB | Mayo Clinic
CAR T-Cells: Subacute and late toxicities beyond CRS
Nirali N. Shah, MD, MHSc | National Institute of Health
PRESENTATION
Gene Therapy INDs and Regulatory Considerations for Accelerated Development Session
Moderator: Anne Chew, PhD | Penn Medicine
Multiple Versions of Gene Therapy Products
Wilson W. Bryan, MD | U.S. Food and Drug Administration
PRESENTATION
Expediting Clinical Development for Cell and Gene Therapies - Applying Master Protocol Concept in Early-Phase Trials
Ke Liu, MD, PhD | Sana Biotechnology
PRESENTATION
Regulatory Considerations to Accelerate Gene Therapy Development
Jiwen Zhang, PhD | Passage Bio
PRESENTATION
Parent-Child Development Strategy: A novel clinical and regulatory framework to evaluate multiple generations of NY-ESO1 targeted cell therapies in rapid sequence
Aiman Shalabi, PharmD, MBA | GlaxoSmithKline
(Consent to Post Not Granted)
Updates on Approved CAR T Cell Therapies Session
Moderator: David L. Porter, MD | Penn Medicine
Mechanisms of Treatment Resistance and Toxicity Related Markers in Context of Axicabtagene Ciloleucel for Lymphoma
Adrian Bot, MD, PhD | Kite
PRESENTATION
International Supply Chain Expansion and Approvals During COVID
Amir Hefni, PhD, MBA | Novartis
PRESENTATION
Lisocabtagene Maraleucel Combination Strategies in Lymphoma
Joseph Grosso, PhD | Bristol Myers Squibb
Track 6 Solid Tumor CARs 9:00 am EDT
Introductions by:
David L. Porter, MD | Penn Medicine
Solid Tumor CARs – ONE Session
Moderator: Partow Kebriaei, MD | MD Anderson
Driving CARs in Solid Tumors: The promise and challenges
Partow Kebriaei, MD | The University of Texas MD Anderson Cancer Center
PRESENTATION
GBM Trials
Donald O’Rourke, MD | Penn Medicine
PRESENTATION
Prostate Cancer Trials
Naomi B. Haas, MD | Penn Medicine
PRESENTATION
Solid Tumor CARs – “TOO” Session
Moderator: Mark H. O'Hara, MD | Penn Medicine
Muc1 Trials
Mark H O'Hara, MD | Penn Medicine
PRESENTATION
MESO/Pancreatic
Janos L. Tanyi, MD, PhD | Penn Medicine
PRESENTATION
What’s “Neo” in Solid Tumors Session
Moderator: Gerald P. Linette, MD, PhD | Penn Medicine
Chromosomal Instability and Immune Evasion in Cancer Evolution
Charles Swanton, FRCP PhD FMedSci, FAACR, FRS | Cancer Research UK
(Consent to Post Not Granted)
Immunotherapy for Clonal Driver Neoantigens
Gerald P. Linette, MD, PhD | Penn Medicine
(Consent to Post Not Granted)
Toward Commercializing Tumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors
Maria Fardis, PhD, MBA | Iovance Biotherapeutics
PRESENTATION
Track 7 Financial Implications 9:00 am EDT
Introduction by:
David L. Porter, MD | Penn Medicine
Financial Implications Session
Moderator: Kevin B. Mahoney, DBA | Penn Medicine
Pricing Tolerance and the Evolution of Cell Therapy Costs of Care
Richard T. Maziarz, MD | Oregon Health & Science University
PRESENTATION
How do We Pay for the Cell and Gene Therapy Revolution?
Kevin B. Mahoney, DBA | Penn Medicine
PRESENTATION
Why do We Need to Keep Costs Down for Cell Therapies? A few ideas for how to do it
Ezekiel J. Emanuel, MD, PhD | University of Pennsylvania
PRESENTATION
Track 8 From Local to Global: Development of Engineered Cell & Gene Therapies 9:00 am EDT
Introductions by:
Stephan A. Grupp, MD, PhD | Children’s Hospital of Philadelphia
Lessons Learned for Stimulating CAR-T Research and Commercialization: USA, UK, Canada and Australia Session
Moderator: Bruce L. Levine, PhD | Penn Medicine
USA: A View from Cellicon Valley
Bruce L. Levine, PhD | US: Cellicon Valley
Australia Cell and Gene Therapy Research and Commercialization: Lessons learned
Simon Harrison, MBBS, MRCP (UK), PhD, FRCPath (UK), FRACP | Australia: Peter MacCallum Cancer Centre
PRESENTATION
Tackling Challenges: A look at lessons learned from the UK
Matthew Durdy, MA, MBA | Cell and Gene Therapy Catapult
PRESENTATION
Canada’s Experience in Commercializing Regenerative, Cell and Gene Therapies
Michael May, PhD | Centre for Commercialization of Regenerative Medicine
PRESENTATION
Stimulating Cross-Border Collaborative Research in CGT Session
Moderator: Anthony Ting, PhD | Bone Therapeutics
Cross-Border Partnerships to Accelerate Cell Manufacturing Technologies: Creating a globally-experienced workforce and developing unique supply chain solutions
Krishnendu Roy, PhD | Georgia Institute of Technology
Exploiting the CAR Technology to Quell Inflammatory Tissue Damage
Alberto Sanchez Fueyo, MD | Kings College London
Perspectives from ISCT
Anthony Ting, PhD | Bone Therapeutics
PRESENTATION
Dissemination of CAR T Clinical Program Expertise Session
Moderator: Robert E. Richards, MSBI, MBA| Penn Medicine
CARs Cruising Down the Highway: From academic to community medicine
Robert E. Richards, MSBI, MBA | Penn Medicine
PRESENTATION
Sarah Cannon’s Approach to Offering CAR T Therapy in the Community
Rocky Billups, MS | Sarah Cannon
PRESENTATION
Dissemination of CAR T Trials-Platforms and Partnerships
Rimas Orentas, PhD | Seattle Children’s Hospital
PRESENTATION
Welcome
Amy Gutmann, PhD | University of Pennsylvania
Keynote Address
Engineering Smarter T Cells
Stanley R. Riddell, MD | Fred Hutchinson Cancer Research Center
PRESENTATION
Cell and Gene Startups and Innovation in Cellicon Valley
Moderator: John S. Swartley, MBA, PhD | University of Pennsylvania
Aimee S. Payne, MD, PhD | Founder, Cabaletta Bio
Debora Barton, MD | CMO, Carisma Therapeutics
Usman “Oz” Azam, MD | CEO, Tmunity Therapeutics
Jeffrey D, Marrazzo, MBA, MPA | CEO, Spark Therapeutics
Audrey Greenberg, MBA, CPA | Co-Founder and Executive Managing Director, The Discovery Labs
Live Q&A For Concurrent Sessions
Featuring Presenters and Moderators from Pre-recorded concurrent sessions
There are a total of 8 tracks. Scroll left and right to view all tracks.
Track 1
Nursing
CNE-Accredited
Track 2 Pediatric Care
Track 3 Pre-Clinical / Manufacturing
Track 4 Next-Gen Clinical Research
Track 5 Regulatory and Commercial Development
Track 6 Solid Tumor CARs
Track 7 Financial Implications
Track 8 From Local to Global: Development of Engineered Cell & Gene Therapies
Track 1
Nursing
CNE-Accredited
3:00 pm EDT
Q&A
Joint Adult and Pediatric Sessions - Nursing and Patient Care
The Use of CRISPR Technology in the Treatment of Malignant and Non-Malignant Diseases:
Making CAR T Cells “CRISPeR”
Track 1
Nursing
CNE-Accredited
3:15 pm EDT
Q&A
Joint Adult and Pediatric Sessions - Nursing and Patient Care
The Use of CRISPR Technology in the Treatment of Malignant and Non-Malignant Diseases:
Nursing Considerations / Implications for Patients with SCD in the Era of Gene Tx with panel
Track 1
Nursing
CNE-Accredited
3:30 pm EDT
Q&A
Pediatric Nursing Session
Immunotherapy in Pediatrics
AML/CART 33: Nursing Considerations during COVID Pandemic
Nursing Considerations for U CART in Pediatrics
Q&A
Adult Nursing Session
Preparing for an Autologous Stem Cell Transplant
Preparing for an Allogenic Transplant
COVID Management of Liquid Oncology Patients
Updates on Immunotherapies in Myeloma
Late Effects and Survivorship Care Following Donor Stem Cell Transplant: What to Expect After the 1st Year?
Track 2 Pediatric Care 3:00 pm EDT
Q&A
Future of Gene Therapy in Pediatrics Session
Clinical Overview/Impact
Gene Therapy Techniques
Track 2 Pediatric Care 3:15 pm EDT
Q&A
Implication of Gene Therapy Treatment in Pediatrics Session
Hemoglobinopathies
Immune deficiencies
Leukodystrophies
Track 3 Pre-Clinical / Manufacturing 3:00 pm EDT
Q&A
Target Discovery and Immunogenicity Session
Antibody Discovery for New CAR Constructs
Immune Responsiveness or Immune Ignorance?
Immune Health
Track 3 Pre-Clinical / Manufacturing 3:15 pm EDT
Q&A
Viral Vector Free Delivery Session
Overview/Survey of Tech
Electro-mechanical Transfection
Transient Cell Volume Exchange
Enabling the Next Wave of Non-Viral Cell Therapies
Track 3 Pre-Clinical / Manufacturing 3:30 pm EDT
Q&A
Gene Delivery and Editing for Better CARs Session
CRISPR and Beyond
PiggyBac and High-Fidelity Gene Editing for Fully Allogeneic CAR-T
Sleeping Beauty in Trials
Track 4 Next-Gen Clinical Research 3:00 pm EDT
Q&A
Newest Model CARs Session
Engineering Remote-Controllable CAR T Cells for Cancer Immunotherapy
T Cell Antigen Couplers
in vivo CAR's
Track 4 Next-Gen Clinical Research 3:15 pm EDT
Q&A
CAR's on the Unpaved Road Session
CAR's in Fibrosis
CAAR's PV by Cabaletta
CAR's in HIV
Track 4 Next-Gen Clinical Research 3:30 pm EDT
Q&A
Allogeneic and Donor Derived CAR T Cells, NKs, iPSC's Session
Allo CARs Intro
Making Allogeneic CAR T Therapy a Reality for Patients: A pathway to controlling rejection
FT536 – An iPSC-Derived, Off-the-Shelf Multiplexed Engineered CAR MICA/B NK Cell Product Targeting Solid Tumors
Donor-Derived Gene-Edited Allogeneic CAR-T
Track 4 Next-Gen Clinical Research 3:45 pm EDT
Q&A
CAR-T Vaccine Booster Session
RNA Vaccine Boosting CAR T Cells
CD19 CAR T “Booster” T-APCs
CMV Vaccine
Track 5 Regulatory and Commercial Development 3:00 pm EDT
Q&A
Managing Toxicities Session
Consistency in Grading and Reporting
Pathophysiology of Neurotoxicity
CAR T-Cells: Subacute and late toxicities beyond CRS
Track 5 Regulatory and Commercial Development 3:15 pm EDT
Q&A
Gene Therapy INDs and Regulatory Considerations for Accelerated Development Session
Multiple Versions of Gene Therapy Products
Expediting Clinical Development for Cell and Gene Therapies - Applying Master Protocol Concept in Early-Phase Trials
Regulatory Considerations to Accelerate Gene Therapy Development
Parent-Child Development Strategy: A novel clinical and regulatory framework to evaluate multiple generations of NY-ESO1 targeted cell therapies in rapid sequence
Track 5 Regulatory and Commercial Development 3:30 pm EDT
Q&A
Updates on Approved CAR T Cell Therapies Session
Mechanisms of Treatment Resistance and Toxicity Related Markers in Context of Axicabtagene Ciloleucel for Lymphoma
International Supply Chain Expansion and Approvals During COVID
Define CD4 CDA Doses in CAR T Cell Therapy
Track 6 Solid Tumor CARs 3:00 pm EDT
Q&A
Solid Tumor CARs - ONE Session
Driving CARs in Solid Tumors: The promise and challenges
GBM Trials
Prostate Cancer Trials
Track 6 Solid Tumor CARs 3:15 pm EDT
Q&A
Solid Tumor CARs - "TOO" Session
Muc1 Trials
MESO/Pancreatic
Track 6 Solid Tumor CARs 3:30 pm EDT
Q&A
What’s “Neo” in Solid Tumors Session
Chromosomal Instability and Immune Evasion in Cancer Evolution
Immunotherapy for Clonal Driver Neoantigens
Toward Commercializing Tumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors
Track 7 Financial Implications 3:00 pm EDT
Q&A
Financial Implications Session
Pricing Tolerance and the Evolution of Cell Therapy Costs of Care
How do We Pay for the Cell and Gene Therapy Revolution?
Why do We Need to Keep Costs Down for Cell Therapies? A few ideas for how to do it
Track 8 From Local to Global: Development of Engineered Cell & Gene Therapies 3:00 pm EDT
Q&A
Lessons Learned for Stimulating CAR-T Research and Commercialization: USA, UK, Canadam and Australia Session
USA: A View from Cellicon Valley
Australia Cell and Gene Therapy Research and Commercialization: Lessons learned
Tackling Challenges: A look at lessons learned from the UK
Canada’s Experience in Commercializing Regenerative, Cell and Gene Therapies
Track 8 From Local to Global: Development of Engineered Cell & Gene Therapies 3:15 pm EDT
Q&A
Stimulating Cross-Border Collaborative Research in CGT Session
Cross-Border Partnerships to Accelerate Cell Manufacturing Technologies: Creating a globally-experienced workforce and developing unique supply chain solutions
Exploiting the CAR Technology to Quell Inflammatory Tissue Damage
Perspectives from ISCT
Track 8 From Local to Global: Development of Engineered Cell & Gene Therapies 3:30 pm EDT
Q&A
Dissemination of CAR T Clinical Program Expertise
CARs Cruising Down the Highway: From academic to community medicine
Sarah Cannon’s Approach to Offering CAR T Therapy in the Community
Dissemination of CAR T Trials-Platforms and Partnerships